Products
Our pipeline: Delivering first-in-class immunotherapies of activation and regulation
Five clinical assets
- Immuno-Oncology
- Immuno-Inflammation
Product candidate
Indication (targets)
Research
IND-enabling
Phase 1
Phase 2
Phase 3
CLEC-1 antagonist
Immuno-Oncology
Significant partnerships with Servier, Boehringer Ingelheim and Veloxis Pharmaceuticals for up to €1.6Bn in milestones (€95 M already received since 2016)
The 3 areas of expertise
Three areas of expertise are being developed within our immunology research platform:
- T-cell based vaccination
- Immuno-Oncology (focus on myeloid targets)
- Auto-Immunity & Inflammation